This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data drop earlier this year.

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Photo: Christophe Gateau/dpa (Photo by Christophe Gateau/picture alliance via Getty Images) ...

In one of the most far-reaching changes to Pakistan's higher education admission system in recent years, Higher Education Commission Pakistan has centralised the MPhil and PhD admission process by ...

The Higher Education Commission of Pakistan (HEC) on Monday announced the launch of a “fully online and paperless” degree attestation system to facilitate students. In December last year, the HEC said ...

https://www.khaleejtimes.com/business-technology-review/free-zones-diversify-uaes-business-ecosystemNot long ago, Ras Al Khaimah was often viewed as the UAE’s ...

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution Medicines is not resting on its laurels. The Bay Area biotech has spent several ...

PARIS — RAS Luxury Skincare, the Indian farm-to-face brand, closed a 65 Crores, or $7.5 million, Series B funding round led by Dabur Ventures. Dabur Ventures is the venture arm of the largest ...

How the UN coordinates global development and human rights efforts at this ODU Model UN event. ODU presents Model UN presenting subjects from poverty and hunger to human rights and global development, ...

• Bold attempt: American rock climber Alex Honnold summited the Taipei 101 skyscraper — with no ropes or safety net — in an event broadcast live. • New heights: The 1,667-foot Taipei 101 is one of the ...

Spinal deformities such as scoliosis and kyphosis are among the most serious complications of neurofibromatosis type 1 (NF1), a genetic disorder that affects about one in 3,000 people. These ...

TAMPA, Fla. and LONDON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today ...